Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergy & Immunology
Pediatric allergies-focused company acquires rights to Twinject for anaphylaxis
August 11th, 2005
Verus Pharmaceuticals, Inc., a pediatric-oriented company identifying, developing and delivering medical systems for children and those who care for them, announced it has acquired exclusive worldwide rights to Twinject from Hollister-Stier Laboratories LLC. Twinject, an epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions (anaphylaxis), was approved by the U.S. Food and Drug Administration (FDA) in 2003; 2 dosages are now approved for self-administration (0.3 mg and 0.15 mg). In addition to Twinject, Verus has acquired rights to other intellectual property and assets, including complementary and next generation device designs and...
Source: Women's Health Weekly (2005-08-11)
|
